Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
The company plans to triple its biomanufacturing R&D capacity beyond what it is currently and also develop new software programs. The company has more than 30 customers, ranging from startups to large firms.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
The company, partnered with Beam Therapeutics, Verily Life Sciences and academic institutions, plans to use gene editing to tackle coronary artery disease. However, experience with gene therapy indicates cost could be a hurdle.
The company has enrolled nearly 250,000 members across six states so far in 2018. Oscar has also projected sales of more than $1 billion in gross premium revenue.
The investment could pave the way for the kind of joint ventures and collaborations that Verily has embarked on with the likes of Sanofi, GSK, and others.